EQS-News: Kinarus AG / Key word(s): Agreement/Financing Kinarus receives 7 Million CHF Grant from the Swiss Federal Funding Programme for COVID-19 Medicines 13.12.2021 / 08:00 Kinarus AG has been awarded a grant from the Swiss Federal Funding Programme for the development of COVID-19 Medicines .
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.